Omalizumab may protect allergic patients against COVID-19: A systematic review.

World Allergy Organ J · 2023 · PMC9826982 · PMID 36644451

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

38 In adults and children omalizumab treatment (for 6 months) increased IFN production against influenza virus A (in a statistically significant way), also a positive trend versus RV and an improvement in control of asthma symptoms were observed. 3 , 21 It has also been supposed for SARS-CoV-2 (even if there are not solid studies about this hypothesis).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.